Ozmosi | Ferric citrate Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Ferric citrate

Pronounced as: fer-ik si-trate

Alternative Names: ferric citrate, krx-0502, krx 0502, krx0502, auryxia
Clinical Status: Active
Latest Update: 2026-02-17
Latest Update Note: Clinical Trial Update

Product Description

Ferric citrate (FC) is an iron-containing phosphate binder that has been shown to effectively decrease serum phosphate, increase hemoglobin, and replete iron stores in patients with chronic kidney disease. Intestinal absorption of iron from FC results in increases in serum iron, ferritin, and transferrin saturation, effects that occur over 12 to 24 weeks and subsequently appear to plateau.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27236135/)

Mechanisms of Action: TFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Brazil | European Medicines Agency | Hungary | Ireland | Italy | Japan | Latvia | Lithuania | Pakistan | Poland | Portugal | Sweden | Switzerland | Taiwan | Turkey | United States

Approved Indications: None

Known Adverse Events: None

Company: Akebia
Company Location: Eastern America
Company Founding Year: 2012
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ferric citrate

Countries in Clinic: Bangladesh, United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Anemia|Anemia, Iron-Deficiency|Hyperphosphatemia|Kidney Failure, Chronic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT07381426

IRB-DMC/2025/291

P3

Not yet recruiting

Anemia

2026-12-31

2026-02-03

Primary Endpoints

NCT04523727

KRX-0502-308

P3

Suspended

Kidney Failure, Chronic|Hyperphosphatemia

2026-12-01

22%

2026-02-18

NCT05085275

FRONTIER

P3

Completed

Hyperphosphatemia|Anemia, Iron-Deficiency|Kidney Failure, Chronic

2024-01-24

14%

2025-08-27

Primary Endpoints|Treatments